The MRI-confirmed infarction with MVO guided the initiation of secondary prevention therapy with statins, ACE inhibitors, beta-blockers, and single antiplatelet therapy, while avoiding dual antiplatelet therapy due to bleeding risk. This evidence concerns the gene ACE and infarction.